



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

November 2018





© 2019 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS  
Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

November 2018

N = 7342



Health Authority	Male	Female	All
FRASER	1431	421	1852
INTERIOR	392	99	491
NORTHERN	130	82	212
VANCOUVER COASTAL	3405	452	3857
VANCOUVER ISLAND	748	148	896
	<b>6106</b>	<b>1202</b>	<b>7308</b>
		<b>Unknown/not stated:</b>	<b>34</b>
		<b>Total:</b>	<b>7342</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2013 - November 2018)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2013 - November 2018)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (November 2013 - November 2018)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (November 2013 - November 2018)






### 1.6 Percent Distribution of Active Participants by CD4 Count (November 2013 - November 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(November 2013 - November 2018)





### 1.8 Active and Inactive Participants (November 2013 - November 2018)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (November 2013 - November 2018)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (November 2013 - November 2018)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(November 2013 - November 2018)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (November 2013 - November 2018)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(November 2013 - November 2018)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (November 2013 - November 2018)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT (November 2013 - November 2018)





### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (November 2013 - November 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





### 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(November 2013 - November 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts (November 2013 - November 2018)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (November 2013 - November 2018)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (November 2013 - November 2018)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (November 2013 - November 2018)





### 2.1 Duration of ARV treatment in the Province of BC, 1987-2018 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	5	0	5	5	700	5	<40	3
1988	27	7	0	7	7	450	7	<40	3
1989	25	55	1	56	46	495	53	<40	3
1990	24	54	1	55	51	520	53	<40	3
1991	24	38	3	41	30	580	40	<40	3
1992	24	65	6	71	55	550	70	<40	3
1993	23	137	15	152	141	540	149	<40	3
1994	22	81	11	92	82	570	90	<40	3
1995	22	134	21	155	129	530	150	<40	3
1996	20	358	57	415	360	590	399	<40	3
1997	18	294	36	330	289	630	317	<40	3
1998	17	208	47	255	219	560	242	<40	3
1999	17	167	41	208	184	580	194	<40	3
2000	17	127	34	161	139	580	154	<40	3
2001	17	123	30	153	130	600	145	<40	3
2002	16	128	25	153	123	610	142	<40	3
2003	15	160	29	189	162	635	182	<40	3
2004	14	171	42	213	176	600	200	<40	3
2005	13	192	45	237	208	625	222	<40	3
2006	12	194	38	232	199	610	223	<40	3
2007	11	258	48	306	258	595	290	<40	3
2008	10	298	67	365	297	630	346	<40	3
2009	9	329	72	401	342	660	376	<40	3
2010	8	292	68	360	301	670	333	<40	3
2011	7	336	74	410	354	680	388	<40	3
2012	6	287	64	351	303	700	343	<40	3
2013	5	277	66	343	287	670	324	<40	3
2014	4	294	53	347	279	700	329	<40	3
2015	3	295	50	345	289	680	322	<40	3
2016	2	290	60	350	282	632	323	<40	3
2017	2	243	43	286	247	640	269	<40	3
2018	0	222	58	280	250	600	273	<40	3
<b>Total:</b>		<b>6119</b>	<b>1205</b>	<b>7324</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	7182	747	2326	<40	2077	590
FEB-2017	7134	754	1914	<40	1740	590
MAR-2017	7186	744	2204	<40	2018	600
APR-2017	7178	746	1966	<40	1770	590
MAY-2017	7224	744	2276	<40	2058	590
JUN-2017	7245	752	2120	<40	1953	596
JUL-2017	7241	753	1965	<40	1789	580
AUG-2017	7266	757	2106	<40	1884	590
SEP-2017	7222	762	2042	<40	1837	610
OCT-2017	7244	770	2187	<40	1938	610
NOV-2017	7240	766	2074	<40	1873	610
DEC-2017	7227	775	1740	<40	1537	610
JAN-2018	7293	755	2385	<40	2103	610
FEB-2018	7256	765	1904	<40	1741	610
MAR-2018	7278	774	2050	<40	1827	617
APR-2018	7264	780	2082	<40	1839	620
MAY-2018	7287	780	2149	<40	1925	600
JUN-2018	7293	795	2008	<40	1786	610
JUL-2018	7299	796	2039	<40	1808	600
AUG-2018	7298	801	2093	<40	1853	610
SEP-2018	7254	805	2016	<40	1747	630
OCT-2018	7346	784	2169	<40	1885	610
NOV-2018	7342	789	2092	<40	1701	630

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	1402	3157	88	140	80	417
FEB-2017	1455	2851	80	1874	70	400
MAR-2017	1408	3137	99	635	89	380
APR-2017	1423	3092	94	545	85	420
MAY-2017	1394	3284	85	180	75	420
JUN-2017	1384	3368	76	197	69	480
JUL-2017	1404	3259	67	436	60	500
AUG-2017	1397	3352	78	160	68	495
SEP-2017	1454	3064	74	323	66	415
OCT-2017	1428	3244	91	218	80	470
NOV-2017	1448	3135	80	133	69	370
DEC-2017	1478	3043	60	53	51	380
JAN-2018	1430	3299	78	872	70	365
FEB-2018	1476	3102	79	1036	65	440
MAR-2018	1462	3168	75	59	70	485
APR-2018	1480	3139	72	634	63	497
MAY-2018	1463	3228	91	<40	82	455
JUN-2018	1470	3234	68	2980	63	440
JUL-2018	1473	3257	68	<40	54	555
AUG-2018	1508	3139	63	56	54	487
SEP-2018	1553	2955	88	164	81	410
OCT-2018	1483	3286	82	<50	71	350
NOV-2018	1499	3263	81	77	68	480

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2017	7140	1402	21	21	141	142	-6	12876
FEB-2017	7102	1455	10	24	136	182	-38	12910
MAR-2017	7147	1408	17	19	189	139	45	12936
APR-2017	7139	1423	12	20	143	151	-8	12968
MAY-2017	7194	1394	7	22	170	126	55	13002
JUN-2017	7209	1384	10	24	151	138	15	13032
JUL-2017	7202	1404	7	14	134	142	-7	13051
AUG-2017	7229	1397	10	25	156	137	27	13081
SEP-2017	7185	1454	12	16	137	180	-44	13110
OCT-2017	7212	1428	7	6	184	151	27	13123
NOV-2017	7205	1448	16	19	142	149	-7	13158
DEC-2017	7197	1478	5	18	158	175	-8	13189
JAN-2018	7253	1430	13	12	192	127	56	13218
FEB-2018	7220	1476	11	27	123	169	-33	13255
MAR-2018	7238	1462	17	21	152	134	18	13282
APR-2018	7230	1480	13	15	153	159	-8	13304
MAY-2018	7258	1463	9	12	171	144	28	13329
JUN-2018	7257	1470	13	16	149	150	-1	13351
JUL-2018	7257	1473	13	14	158	152	0	13377
AUG-2018	7265	1508	9	27	155	162	8	13416
SEP-2018	7222	1553	16	15	154	192	-43	13442
OCT-2018	7318	1483	8	19	217	128	96	13478
NOV-2018	7324	1499	4	8	173	170	6	13502

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2017	61	6615	443	63	<b>7182</b>	0.85%	92.11%	6.17%	0.88%	<b>100.00%</b>
FEB-2017	60	6579	440	55	<b>7134</b>	0.84%	92.22%	6.17%	0.77%	<b>100.00%</b>
MAR-2017	60	6629	439	58	<b>7186</b>	0.83%	92.25%	6.11%	0.81%	<b>100.00%</b>
APR-2017	58	6633	428	59	<b>7178</b>	0.81%	92.41%	5.96%	0.82%	<b>100.00%</b>
MAY-2017	62	6665	438	59	<b>7224</b>	0.86%	92.26%	6.06%	0.82%	<b>100.00%</b>
JUN-2017	57	6691	438	59	<b>7245</b>	0.79%	92.35%	6.05%	0.81%	<b>100.00%</b>
JUL-2017	61	6685	433	62	<b>7241</b>	0.84%	92.32%	5.98%	0.86%	<b>100.00%</b>
AUG-2017	61	6696	448	61	<b>7266</b>	0.84%	92.16%	6.17%	0.84%	<b>100.00%</b>
SEP-2017	57	6677	431	57	<b>7222</b>	0.79%	92.45%	5.97%	0.79%	<b>100.00%</b>
OCT-2017	58	6691	438	57	<b>7244</b>	0.80%	92.37%	6.05%	0.79%	<b>100.00%</b>
NOV-2017	59	6680	445	56	<b>7240</b>	0.81%	92.27%	6.15%	0.77%	<b>100.00%</b>
DEC-2017	58	6666	447	56	<b>7227</b>	0.80%	92.24%	6.19%	0.77%	<b>100.00%</b>
JAN-2018	58	6729	451	55	<b>7293</b>	0.80%	92.27%	6.18%	0.75%	<b>100.00%</b>
FEB-2018	61	6685	451	59	<b>7256</b>	0.84%	92.13%	6.22%	0.81%	<b>100.00%</b>
MAR-2018	62	6708	453	56	<b>7279</b>	0.85%	92.16%	6.22%	0.77%	<b>100.00%</b>
APR-2018	58	6699	449	58	<b>7264</b>	0.80%	92.22%	6.18%	0.80%	<b>100.00%</b>
MAY-2018	64	6711	455	58	<b>7288</b>	0.88%	92.08%	6.24%	0.80%	<b>100.00%</b>
JUN-2018	61	6725	449	58	<b>7293</b>	0.84%	92.21%	6.16%	0.80%	<b>100.00%</b>
JUL-2018	53	6730	461	55	<b>7299</b>	0.73%	92.20%	6.32%	0.75%	<b>100.00%</b>
AUG-2018	54	6734	454	56	<b>7298</b>	0.74%	92.27%	6.22%	0.77%	<b>100.00%</b>
SEP-2018	51	6686	458	59	<b>7254</b>	0.70%	92.17%	6.31%	0.81%	<b>100.00%</b>
OCT-2018	53	6764	475	54	<b>7346</b>	0.72%	92.08%	6.47%	0.74%	<b>100.00%</b>
NOV-2018	54	6761	477	50	<b>7342</b>	0.74%	92.09%	6.50%	0.68%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3169 45%	6 20%	2902 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3198 46%	7 37%	2928 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3838 54%
SEP-2017	10 34%	3213 46%	10 34%	2950 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3775 54%
OCT-2017	5 38%	3241 46%	5 38%	2983 42%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 15%	245 3%	6 46%	3715 53%
NOV-2017	9 26%	3280 47%	8 23%	3024 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	25 71%	3661 52%
DEC-2017	10 32%	3286 47%	10 32%	3032 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	22 71%	3612 52%
JAN-2018	10 36%	3320 47%	9 32%	3076 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3635 51%
FEB-2018	13 35%	3321 47%	12 32%	3079 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3586 51%
MAR-2018	10 37%	3340 47%	10 37%	3104 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3567 50%
APR-2018	5 23%	3347 47%	5 23%	3115 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3540 50%
MAY-2018	9 39%	3355 47%	8 35%	3129 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3516 50%
JUN-2018	6 30%	3373 48%	6 30%	3149 44%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3486 49%
JUL-2018	7 28%	3401 48%	7 28%	3178 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3454 49%
AUG-2018	13 33%	3398 48%	14 36%	3186 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3418 48%
SEP-2018	4 15%	3380 48%	3 12%	3166 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3376 48%
OCT-2018	11 31%	3421 48%	9 26%	3208 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	478 7%	25 71%	3388 47%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	7	54%	3731	53%
NOV-2017	26	74%	3693	53%
DEC-2017	21	68%	3665	52%
JAN-2018	18	64%	3711	52%
FEB-2018	24	65%	3680	52%
MAR-2018	17	63%	3673	52%
APR-2018	17	77%	3662	52%
MAY-2018	14	61%	3662	52%
JUN-2018	14	70%	3663	52%
JUL-2018	18	72%	3656	52%
AUG-2018	25	64%	3651	52%
SEP-2018	22	85%	3635	52%
OCT-2018	24	69%	3687	52%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
NOV-2018	9 38%	3426 48%	8 33%	3213 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	0 0%	490 7%	16 67%	3354 47%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
NOV-2018	15	63%	3668	51%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1359 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1359 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1396 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1389 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1364 46%	6 100%	1396 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1324 45%	10 83%	1392 48%	1 8%	205 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%
DEC-2017	0 0%	7 0%	1 7%	1295 45%	14 93%	1397 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	196 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1258 44%	15 100%	1422 49%	0 0%	190 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1247 43%	10 91%	1439 50%	0 0%	188 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1223 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1210 43%	5 100%	1443 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1191 42%	11 92%	1435 51%	0 0%	177 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1171 42%	7 70%	1444 52%	1 10%	170 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1157 42%	11 69%	1426 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1134 42%	6 86%	1410 52%	0 0%	160 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1123 41%	15 83%	1450 53%	0 0%	155 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

**2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)**

	tipranavir			
	Initial		All	
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%
DEC-2017	0	0%	1	0%
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1460 53%	0 0%	147 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%

Definitions:

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)**

	tipranavir			
	Initial		All	
NOV-2018	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	1 100%	802 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	5 71%	800 38%	0 0%	269 13%	0 0%	767 36%	2 29%	300 14%
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	758 36%	1 25%	301 14%
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	725 36%	1 50%	314 16%
JUL-2018	3 60%	723 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	707 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	697 36%	0 0%	234 12%	0 0%	710 36%	2 40%	324 17%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







**2.8 Number of Participants on Non-Nucleosides by INGREDIENT (continued)**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
NOV-2018	8 80%	687 35%	0 0%	230 12%	0 0%	698 36%	2 20%	323 17%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	0 0%	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	0 0%	0 0%	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	0 0%	0 0%	13 87%	1620 55%	2 13%	601 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	0 0%	0 0%	14 78%	1655 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	0 0%	0 0%	19 86%	1726 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	0 0%	0 0%	12 75%	1757 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	0 0%	0 0%	8 73%	1791 58%	3 27%	592 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	0 0%	0 0%	13 72%	1824 58%	4 22%	596 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%
SEP-2017	0 0%	0 0%	10 71%	1833 58%	4 29%	600 19%	0 0%	50 2%	0 0%	700 22%	0 0%	1 0%
OCT-2017	0 0%	0 0%	8 89%	1879 59%	1 11%	608 19%	0 0%	48 1%	0 0%	708 22%	0 0%	0 0%
NOV-2017	0 0%	0 0%	14 67%	1939 60%	5 24%	611 19%	0 0%	49 2%	2 10%	701 22%	0 0%	0 0%
DEC-2017	0 0%	0 0%	11 69%	1958 60%	5 31%	603 18%	0 0%	48 1%	0 0%	689 21%	0 0%	0 0%
JAN-2018	0 0%	0 0%	9 47%	2006 60%	8 42%	631 19%	0 0%	46 1%	2 11%	688 21%	0 0%	0 0%
FEB-2018	0 0%	0 0%	16 70%	2027 60%	6 26%	642 19%	0 0%	45 1%	1 4%	676 20%	0 0%	0 0%
MAR-2018	0 0%	0 0%	14 100%	2061 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%	0 0%	0 0%
APR-2018	0 0%	0 0%	8 67%	2106 61%	4 33%	654 19%	0 0%	44 1%	0 0%	681 20%	0 0%	0 0%
MAY-2018	0 0%	0 0%	13 65%	2139 61%	4 20%	665 19%	1 5%	42 1%	3 15%	675 19%	0 0%	0 0%
JUN-2018	0 0%	0 0%	7 64%	2174 62%	3 27%	675 19%	0 0%	42 1%	1 9%	678 19%	0 0%	0 0%
JUL-2018	0 0%	0 0%	7 58%	2210 62%	4 33%	676 19%	0 0%	43 1%	1 8%	677 19%	0 0%	0 0%
AUG-2018	0 0%	0 0%	23 79%	2256 62%	5 17%	676 19%	0 0%	42 1%	1 3%	671 19%	0 0%	0 0%
SEP-2018	0 0%	9 0%	5 36%	2262 62%	9 64%	690 19%	0 0%	41 1%	0 0%	656 18%	0 0%	0 0%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	659 18%	0 0%	0 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT (continued)

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
NOV-2018	0 0%	17 0%	9 100%	2340 63%	0 0%	706 19%	0 0%	38 1%	0 0%	650 17%	0 0%	0 0%

Definitions:

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.73	2349	32.42	132	1.82	59	0.81	871	12.02
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	867	11.97
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.72	1676	23.21	2427	33.61	127	1.76	57	0.79	861	11.92
OCT-2017	2050	28.30	1674	23.11	2476	34.18	124	1.71	57	0.79	863	11.91
NOV-2017	2003	27.67	1668	23.04	2519	34.79	119	1.64	56	0.77	875	12.09
DEC-2017	1998	27.65	1660	22.97	2531	35.02	115	1.59	56	0.77	867	12.00
JAN-2018	2010	27.56	1645	22.56	2595	35.58	117	1.60	55	0.75	871	11.94
FEB-2018	1968	27.12	1630	22.46	2615	36.04	116	1.60	59	0.81	868	11.96
MAR-2018	1979	27.19	1616	22.20	2647	36.36	113	1.55	56	0.77	868	11.92
APR-2018	1937	26.67	1596	21.97	2698	37.14	114	1.57	58	0.80	861	11.85
MAY-2018	1931	26.50	1575	21.61	2738	37.57	114	1.56	58	0.80	872	11.96
JUN-2018	1912	26.22	1564	21.45	2790	38.26	113	1.55	58	0.80	856	11.74
JUL-2018	1888	25.87	1567	21.47	2820	38.64	110	1.51	55	0.75	859	11.77
AUG-2018	1866	25.57	1549	21.22	2865	39.26	111	1.52	56	0.77	851	11.66
SEP-2018	1832	25.26	1533	21.13	2879	39.69	109	1.50	59	0.81	842	11.61
OCT-2018	1855	25.25	1529	20.81	2946	40.10	104	1.42	54	0.74	858	11.68
NOV-2018	1843	25.10	1521	20.72	2964	40.37	106	1.44	50	0.68	858	11.69

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	6	2	0	0	2	2	435
NOV-2017	19	2	1	6	3	7	430
DEC-2017	18	2	2	4	4	5	390
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	2	6	490
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	14	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	8	2	2	2	0	2	185

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2017	11552	3372
FEB-2017	11577	3379
MAR-2017	11628	3428
APR-2017	11654	3443
MAY-2017	11695	3468
JUN-2017	11722	3482
JUL-2017	11754	3512
AUG-2017	11790	3539
SEP-2017	11817	3564
OCT-2017	11874	3618
NOV-2017	11885	3616
DEC-2017	11912	3622
JAN-2018	11970	3664
FEB-2018	11999	3678
MAR-2018	12027	3707
APR-2018	12057	3736
MAY-2018	12092	3761
JUN-2018	12104	3764
JUL-2018	12131	3789
AUG-2018	12145	3784
SEP-2018	12169	3807
OCT-2018	12190	3808
NOV-2018	12236	3834

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
November 2018

N = 7342

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2018

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE









3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2018

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender  
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	11	13	*
	50+	25	36	*
	<b>Total HSDA:</b>	<b>41</b>	<b>54</b>	<b>29</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>69</b>	<b>92</b>	<b>51</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>363</b>	<b>485</b>	<b>274</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	13
	35-49	*	*	40
	50+	*	*	84
<b>Total HSDA:</b>	<b>187</b>	<b>249</b>	<b>137</b>	
<b>Total HA:</b>		<b>660</b>	<b>880</b>	<b>491</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>660</b>	<b>880</b>	<b>491</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	521	701	392
Female	139	179	99

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	491	54	600	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	7	5
	<5 years	16	13
	<b>Total HSDA:</b>	<b>41</b>	<b>29</b>
KOOTENAY BOUNDARY	10 years or more	42	30
	5 years or more	14	11
	<5 years	13	10
	<b>Total HSDA:</b>	<b>69</b>	<b>51</b>
OKANAGAN	10 years or more	221	160
	5 years or more	61	50
	<5 years	81	64
	<b>Total HSDA:</b>	<b>363</b>	<b>274</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	104	71
	5 years or more	38	30
	<5 years	45	36
	<b>Total HSDA:</b>	<b>187</b>	<b>137</b>
<b>Total HA:</b>		<b>660</b>	<b>491</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	385	272
5 years or more	120	96
<5 years	155	123
<b>Total HA:</b>	<b>660</b>	<b>491</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	39	58	12	23
KOOTENAY BOUNDARY	67	119	21	42
OKANAGAN	210	791	61	278
THOMPSON/CARIBOO/SHUSWAP	126	486	36	137
<b>Total:</b>	<b>442</b>	<b>1454</b>	<b>130</b>	<b>480</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>91</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>358</b>	<b>443</b>
FRASER NORTH	0-19	10	10	*
	20-34	115	117	*
	35-49	352	387	*
	50+	529	840	*
	<b>Total HSDA:</b>		<b>1006</b>	<b>1354</b>
FRASER SOUTH	0-19	7	7	5
	20-34	106	108	76
	35-49	348	397	292
	50+	508	749	430
	<b>Total HSDA:</b>		<b>969</b>	<b>1261</b>
<b>Total HA:</b>		<b>2333</b>	<b>3058</b>	<b>1852</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	21	21	11
	20-34	250	256	177
	35-49	810	906	638
	50+	1252	1875	1026
<b>Total HA:</b>		<b>2333</b>	<b>3058</b>	<b>1852</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1773	2349	1431
Female	560	709	421

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1852	51	620	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)







### 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	194	149
	5 years or more	94	73
	<5 years	70	52
	<b>Total HSDA:</b>	<b>358</b>	<b>274</b>
FRASER NORTH	10 years or more	528	384
	5 years or more	262	209
	<5 years	216	182
	<b>Total HSDA:</b>	<b>1006</b>	<b>775</b>
FRASER SOUTH	10 years or more	500	404
	5 years or more	231	191
	<5 years	238	208
	<b>Total HSDA:</b>	<b>969</b>	<b>803</b>
<b>Total HA:</b>		<b>2333</b>	<b>1852</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1222	937
	5 years or more	587	473
	<5 years	524	442
<b>Total HA:</b>		<b>2333</b>	<b>1852</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	137	483	37	70
FRASER NORTH	247	1536	56	249
FRASER SOUTH	210	1316	44	353
<b>Total:</b>	<b>594</b>	<b>3335</b>	<b>137</b>	<b>672</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	194
FRASER NORTH	660
FRASER SOUTH	535
<b>Total:</b>	<b>1389</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	67
	50+	*	*	197
	<b>Total HSDA:</b>		<b>329</b>	<b>474</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>168</b>	<b>217</b>
VANCOUVER	0-19	36	39	7
	20-34	436	447	314
	35-49	1443	1627	1059
	50+	2719	4617	2064
	<b>Total HSDA:</b>	<b>4634</b>	<b>6730</b>	<b>3444</b>
<b>Total HA:</b>		<b>5131</b>	<b>7421</b>	<b>3857</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	39	42	8
	20-34	487	499	351
	35-49	1570	1767	1163
	50+	3035	5113	2335
<b>Total HA:</b>		<b>5131</b>	<b>7421</b>	<b>3857</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4508	6507	3405
Female	621	912	452

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3857	53	630	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	177	148
	5 years or more	80	68
	<5 years	72	67
	<b>Total HSDA:</b>	<b>329</b>	<b>283</b>
RICHMOND	10 years or more	87	63
	5 years or more	42	33
	<5 years	39	34
	<b>Total HSDA:</b>	<b>168</b>	<b>130</b>
VANCOUVER	10 years or more	2599	1849
	5 years or more	1192	903
	<5 years	843	692
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4634</b>	<b>3444</b>
<b>Total HA:</b>	<b>5131</b>	<b>3857</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2863	2060
	5 years or more	1314	1004
	<5 years	954	793
	Never on ART	0	0
<b>Total HA:</b>		<b>5131</b>	<b>3857</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	165	483	55	177
RICHMOND	43	281	12	93
VANCOUVER	584	10634	199	5356
<b>Total:</b>	<b>792</b>	<b>11398</b>	<b>266</b>	<b>5626</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>114</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>314</b>	<b>440</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>119</b>	<b>158</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>714</b>	<b>1007</b>
<b>Total HA:</b>		<b>1147</b>	<b>1605</b>	<b>896</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	103	109	*
	35-49	302	351	*
	50+	736	1139	*
<b>Total HA:</b>		<b>1147</b>	<b>1605</b>	<b>896</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	943	1320	748
Female	204	285	148

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	896	54	520	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	167	138
	5 years or more	72	60
	<5 years	75	57
	<b>Total HSDA:</b>	<b>314</b>	<b>255</b>
NORTH VANCOUVER ISLAND	10 years or more	66	55
	5 years or more	31	24
	<5 years	22	19
	<b>Total HSDA:</b>	<b>119</b>	<b>98</b>
SOUTH VANCOUVER ISLAND	10 years or more	400	283
	5 years or more	157	127
	<5 years	157	133
	<b>Total HSDA:</b>	<b>714</b>	<b>543</b>
<b>Total HA:</b>		<b>1147</b>	<b>896</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	633	476
	5 years or more	260	211
	<5 years	254	209
<b>Total HA:</b>		<b>1147</b>	<b>896</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	832	77	190
NORTH VANCOUVER ISLAND	127	257	41	70
SOUTH VANCOUVER ISLAND	205	1735	44	566
<b>Total:</b>	<b>523</b>	<b>2824</b>	<b>162</b>	<b>826</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	53
NORTH VANCOUVER ISLAND	35
SOUTH VANCOUVER ISLAND	103
<b>Total:</b>	<b>191</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>39</b>	<b>47</b>
NORTH WEST	0-19	*	*	0
	20-34	*	*	8
	35-49	*	*	14
	50+	*	*	31
	<b>Total HSDA:</b>		<b>69</b>	<b>107</b>
NORTHERN INTERIOR	0-19	5	5	*
	20-34	17	20	*
	35-49	71	87	*
	50+	85	141	*
	<b>Total HSDA:</b>		<b>178</b>	<b>253</b>
<b>Total HA:</b>		<b>286</b>	<b>407</b>	<b>212</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	31	36	*
	35-49	107	142	*
	50+	141	222	*
<b>Total HA:</b>		<b>286</b>	<b>407</b>	<b>212</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	175	252	130
Female	111	155	82

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	212	50	560	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	8
	5 years or more	14	8
	<5 years	8	6
	<b>Total HSDA:</b>	<b>39</b>	<b>22</b>
NORTH WEST	10 years or more	29	19
	5 years or more	27	23
	<5 years	13	11
	<b>Total HSDA:</b>	<b>69</b>	<b>53</b>
NORTHERN INTERIOR	10 years or more	69	48
	5 years or more	62	51
	<5 years	47	38
	<b>Total HSDA:</b>	<b>178</b>	<b>137</b>
<b>Total HA:</b>		<b>286</b>	<b>212</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	115	75
	5 years or more	103	82
	<5 years	68	55
<b>Total HA:</b>		<b>286</b>	<b>212</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	37	61	8	9
NORTH WEST	70	158	15	27
NORTHERN INTERIOR	104	444	15	183
<b>Total:</b>	<b>211</b>	<b>663</b>	<b>38</b>	<b>219</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	19
NORTHERN INTERIOR	18
<b>Total:</b>	<b>43</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	22	37	*
	THOMPSON/CARIBOO/SHUSWAP	25	43	*
	<b>Total HA:</b>	<b>59</b>	<b>99</b>	<b>44</b>
FRASER	FRASER EAST	40	50	31
	FRASER NORTH	54	90	43
	FRASER SOUTH	73	105	55
	<b>Total HA:</b>	<b>167</b>	<b>245</b>	<b>129</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	24
	RICHMOND	12	17	8
	VANCOUVER	499	844	389
	<b>Total HA:</b>	<b>536</b>	<b>909</b>	<b>421</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	78	42
	NORTH VANCOUVER ISLAND	15	24	13
	SOUTH VANCOUVER ISLAND	34	76	29
	<b>Total HA:</b>	<b>99</b>	<b>178</b>	<b>84</b>
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	32	61	26
	NORTHERN INTERIOR	61	97	51
	<b>Total HA:</b>	<b>102</b>	<b>169</b>	<b>84</b>
<b>Total:</b>		<b>963</b>	<b>1600</b>	<b>762</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	601	1021	475
Female	362	579	287

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	762	51	500	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.







**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

